From these data, we hypothesize that VPA exerts its anti-tumor activity more specifically in metastatic prostate cells than in non-metastatic prostate cancer cells, in part, by upregulating NDRG1 expression in metastatic prostate cells. This evidence concerns the gene NDRG1 and prostate carcinoma.